Literature DB >> 28417006

First report of serotype 23B Streptococcus pneumoniae isolated from an adult patient with invasive infection in Japan.

A Takamatsu1, M Kawaguchiya1, B Chang1, M Ito1, Y Hirano1, S Katsuta1, S Matsuzaka1, Y Serizawa1, N Kobayashi1.   

Abstract

Serotype 23B Streptococcus pneumoniae was isolated from a 67-year-old Japanese patient with meningitis. This isolate was susceptible to penicillin G, while genotyped as gPISP with a mutation in a penicillin-binding motif in PBP2b. The 23B isolate was assigned to ST11996 that is related to CC439, a dominant group among serotype 23B.

Entities:  

Keywords:  Invasive infection; Japan; Streptococcus pneumoniae; serotype 23B

Year:  2017        PMID: 28417006      PMCID: PMC5388934          DOI: 10.1016/j.nmni.2017.02.008

Source DB:  PubMed          Journal:  New Microbes New Infect        ISSN: 2052-2975


Streptococcus pneumoniae is a major cause of invasive infections, particularly in young children and the elderly worldwide. In Japan, a 13-valent pneumococcal conjugate vaccine (PCV13) has been used for routine immunization of children since 2013, and for adults on a voluntary basis since 2014, leading to a rapid reduction in invasive pneumococcal diseases (IPD) [1]. Since then, an increase of S. pneumoniae with non-vaccine serotypes has been noted for IPD as well as non-IPD [2], [3], [4], [5]. A non-vaccine type, 23B, has not yet been reported in Japan, although its increase was observed in Europe and the USA in the PCV13 era [6], [7], [8], [9]. A fully ambulatory 67-year-old Japanese man with a past history of chronic kidney disease was admitted to our hospital in June 2016 for shaking chills and dysarthria without fever. He had no history of pneumococcal vaccination or recent overseas travel. On physical examination, he was lethargic with neck stiffness. Laboratory tests showed leucocytosis (18570/μL; normal range: 3500–9700/μL), elevated creatine level (6.69 mg/dL; normal range: 0.65–1.09 mg/dL), and elevated C-reactive protein level (47.59 mg/dL; normal range <0.30 mg/dL). Computed tomography (CT) revealed splenic hypoplasia without cerebral herniation (Fig. 1a). Cerebrospinal fluid analysis showed pleocytosis (cell count: 354/mm3), hypoglycorrhachia (0 mg/dL; plasma glucose level: 92 mg/dL), elevated protein (262 mg/dL; normal range: 10–40 mg/dL), and presence of Gram-positive diplococci and pneumococcal antigen. He was diagnosed with pneumococcal meningitis. Ceftriaxone (2 g twice daily) and vancomycin (1 g twice daily) with dexamethasone (10 mg four times daily) were administered intravenously. Streptococcus pneumoniae (MIC of penicillin G ≤0.03 mg/L) was isolated from blood and cerebrospinal fluid, and antibiotics were changed to intravenous ampicillin (3 g three times daily) on the 5th hospital day. Blood cultures turned negative from the 8th hospital day forward. On the 13th hospital day, he complained of low back pain. A T2-weighted MRI revealed increased signal intensity at the L5–S1 level, indicating osteomyelitis (Fig. 1b). Ampicillin was changed to ceftriaxone and oral rifampicin (600 mg/day). The patient was subsequently treated with intravenous antibiotics for 6 weeks, and discharged with oral amoxicillin (2 g/day) for another 2 weeks.
Fig. 1

Enhanced CT scan of the patient's abdomen showing splenic hypoplasia (a), T2-weighted sagittal MRI scan of the patient showing increased signal intensity at the L5–S1 level (b).

The S. pneumoniae isolate designated AT0814 was serotyped as 23B by Quellung reaction, and also by sequential multiplex PCR [10]. The wzx gene sequence of this isolate was identical to that of the 23B strain 1039/41, whereas it showed 81% identity to those of 23F and 23A strains. The isolate AT0814 was found to be susceptible to all the 18 antimicrobials as determined by the broth microdilution test. However, the PBP genotype was determined to be gPISP (pbp2b). Sequence analysis of pbp1a, pbp2b and pbp2x (GenBank Accession Nos KX698435–KX698437) revealed that PBP2b had an amino acid substitution in the penicillin-binding motif (442SSNT445→442SSNA445). PCR testing revealed virulence factor genes pspA (Family 1, clade 1), pspC (Group 4), ply, pavA, phtA, phtB, phtE, nanA, nanB and pcpA, and the absence of erm(B), mefA/E and pilus genes. AT0814 was assigned to ST11996 (allele combination 1-43-388-18-6-679-14) by multilocus sequence typing, which was not grouped into any clonal complex (CC). However, ST11996 showed similarity (four matched alleles) to ST8959 and ST11443 (CC439), both of which were reported for serotype 23B S. pneumoniae in Germany, Saudi Arabia and Qatar. Hence, it appears that AT0814 is genetically related to CC439, one of the dominant clones among serotype 23B [8]. This is the first report of S. pneumoniae serotype 23B in Japan. The isolate AT0814 was derived from IPD, and demonstrated a gPISP genotype and various virulence factors. Special attention must be paid to the prevalence and antimicrobial susceptibility of this serotype in the PCV era.

Conflicts of Interest

None to declare.
  10 in total

1.  Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.

Authors:  Anneke Steens; Marianne A Riise Bergsaker; Ingeborg S Aaberge; Karin Rønning; Didrik F Vestrheim
Journal:  Vaccine       Date:  2013-10-29       Impact factor: 3.641

2.  Revisiting pneumococcal carriage by use of broth enrichment and PCR techniques for enhanced detection of carriage and serotypes.

Authors:  Maria da Gloria Carvalho; Fabiana C Pimenta; Delois Jackson; Alexis Roundtree; Yusra Ahmad; Eugene V Millar; Katherine L O'Brien; Cynthia G Whitney; Adam L Cohen; Bernard W Beall
Journal:  J Clin Microbiol       Date:  2010-03-10       Impact factor: 5.948

3.  The effect of pneumococcal conjugate vaccines on the incidence of invasive pneumococcal disease caused by ten non-vaccine serotypes in Denmark.

Authors:  Hans-Christian Slotved; Tine Dalby; Steen Hoffmann
Journal:  Vaccine       Date:  2016-01-06       Impact factor: 3.641

4.  Nationwide population-based surveillance of invasive pneumococcal disease in Japanese children: Effects of the seven-valent pneumococcal conjugate vaccine.

Authors:  Shigeru Suga; Bin Chang; Kazutoyo Asada; Hideki Akeda; Junichiro Nishi; Kenji Okada; Hiroshi Wakiguchi; Akihiko Maeda; Megumi Oda; Naruhiko Ishiwada; Akihiko Saitoh; Tomohiro Oishi; Mitsuaki Hosoya; Takehiro Togashi; Kazunori Oishi; Toshiaki Ihara
Journal:  Vaccine       Date:  2015-07-31       Impact factor: 3.641

5.  Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014.

Authors:  Satoshi Nakano; Takao Fujisawa; Yutaka Ito; Bin Chang; Shigeru Suga; Taro Noguchi; Masaki Yamamoto; Yasufumi Matsumura; Miki Nagao; Shunji Takakura; Makoto Ohnishi; Toshiaki Ihara; Satoshi Ichiyama
Journal:  Vaccine       Date:  2015-11-19       Impact factor: 3.641

6.  Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era.

Authors:  Mark van der Linden; Stephanie Perniciaro; Matthias Imöhl
Journal:  BMC Infect Dis       Date:  2015-05-05       Impact factor: 3.090

7.  Serotype Changes and Drug Resistance in Invasive Pneumococcal Diseases in Adults after Vaccinations in Children, Japan, 2010-2013.

Authors:  Kimiko Ubukata; Naoko Chiba; Shigeo Hanada; Miyuki Morozumi; Takeaki Wajima; Michi Shouji; Satoshi Iwata
Journal:  Emerg Infect Dis       Date:  2015-11       Impact factor: 6.883

8.  Emerging non-PCV13 serotypes of noninvasive Streptococcus pneumoniae with macrolide resistance genes in northern Japan.

Authors:  M Kawaguchiya; N Urushibara; M S Aung; S Morimoto; M Ito; K Kudo; A Sumi; N Kobayashi
Journal:  New Microbes New Infect       Date:  2015-11-11

9.  Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.).

Authors:  Sandra S Richter; Kristopher P Heilmann; Cassie L Dohrn; Fathollah Riahi; Daniel J Diekema; Gary V Doern
Journal:  Emerg Infect Dis       Date:  2013-07       Impact factor: 6.883

10.  Changes in capsule and drug resistance of Pneumococci after introduction of PCV7, Japan, 2010-2013.

Authors:  Naoko Chiba; Miyuki Morozumi; Michi Shouji; Takeaki Wajima; Satoshi Iwata; Kimiko Ubukata
Journal:  Emerg Infect Dis       Date:  2014-07       Impact factor: 6.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.